Patients with inflammatory bowel disease may have a transforming growth factor-β-, interleukin (IL)-2- or IL-10-deficient state induced by intrinsic neutralizing antibodies

Clinical and Experimental Immunology

Volumn 155, Issue 1, 2009, Pages 65-71

  Ebert, E C ^a,b   Panja, A ^a   Das, K M ^a   Praveen, R ^a   Geng, X ^a   Rezac, C ^a   Bajpai, M ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b NONE   (United States)

Author keywords

CD; IBD; IL 10; IL 2; TGF; UC

Indexed keywords

IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 2 ANTIBODY; NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ARTICLE; COLORIMETRY; CONTROLLED STUDY; CROHN DISEASE; DISEASE PREDISPOSITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ADULT; ANALYSIS OF VARIANCE; AUTOANTIBODIES; CASE-CONTROL STUDIES; CELL LINE, TUMOR; COLITIS, ULCERATIVE; CROHN DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-10; INTERLEUKIN-2; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 57449087458     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2008.03802.x     Document Type: Article

References (25)

1. Gorelik L, Flavell RA. Transforming growth factor-β in T cell biology. Nat Rev Immunol 2002 2 : 46 53.
2. Ohtsuka Y, Sanderson IR. Transforming growth factor-beta: an important cytokine in the mucosal immune response. Curr Opin Gastroenterol 2000 16 : 541 5.
3. Shull MM, Ormsby I, Kier AB et al. Targeted disruption of the mouse TGFβ1 gene results in multifocal inflammatory disease. Nature 1992 359 : 693 99.
4. Hahm K-B, Im Y-H, Parks TW et al. Loss of transforming growth factor β signaling in the intestine contributes to tissue injury in inflammatory bowel disease. Gut 2001 49 : 190 8.
5. Ludviksson BR, Ehrhardt RO, Strober W. TGFβ production regulates the development of the 2, 4, 5-trinitrophenol-conjugated keyhole lipet hemocyanin-induced colonic inflammation in IL-2-deficient mice. J Immunol 1997 159 : 3622 28.
6. Massague J, Chen YG. Controlling TGFβ signaling. Genes Dev 2000 14 : 627 44.
7. Grainger DJ, Mosedale DE, Metcalfe JC. TGFβ in blood: a complex problem. Cytokine Growth Factor Rev 2000 11 : 133 45.
8. Babyatsky MW, Rossiter G, Podolsky DK. Expression of transforming growth factors α and β in colonic mucosa in inflammatory bowel disease. Gastroenterology 1996 110 : 975 84.
9. DiMola FF, Friess H, Schreuren A et al. Transforming growth factor-β and their signaling receptors are coexpressed in Crohn's disease. Ann Surg 1999 229 : 67 75.
10. Xian CJ, Xu X, Mardell E et al. Site-specific changes in transforming growth factor-α and -β1 expression in colonic mucosa of adolescents with inflammatory bowel disease. Scand J Gastroenterol 1999 34 : 591 600.
11. Sadlack B, Merz H, Schorle H, Schimpi A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993 75 : 253 61.
12. Elson CO, Cong Y, McCracken VJ, Dimmitt RA, Lorenz RG, Weaver CT. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev 2005 206 : 260 76.
13. Ruiz PA, Shkoda A, Kim SC, Sartor RB, Haller D. IL-10 gene-deficient mice lack TGF-beta/Smad signaling and fail to inhibit proinflammatory gene expression in intestinal epithelial cells after the colonization with colitogenic Enterococcus faecalis. J Immunol 2005 174 : 2990 99.
14. Bendtzen K, Hansen MB, Ross C, Svenson M. High-avidity autoantibodies to cytokines. Immunol Today 1998 19 : 209 11.
15. Coutinho A, Kazatchkine MD, Avrameas S. Natural autoantibodies. Curr Opin Immunol 1995 7 : 812 18.
16. Meager A, Wadhwa M, Dilger P et al. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol 2003 132 : 128 36.
17. Tiberio L, Caruso A, Pozzi A et al. The detection and biological activity of human antibodies to IL-2 in normal donors. Scand J Immunol 1993 38 : 472 6.
18. Svenson M, Hansen MB, Ross C et al. Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood 1998 91 : 2054 61.
19. Menetrier-Caux C, Briere F, Jouvenne P, Peyron E, Peyron F, Banchereau J. Identification of human IgG autoantibodies specific for IL-10. Clin Exp Immunol 1996 104 : 173 9.
20. Stevceva L, Pavil P, Husband A, Ramsay A, Doe WF. Dextran sulfate sodium-induced colitis is ameliorated in interleukin-4 deficient mice. Genes Immun 2001 2 : 309 16.
21. Melgar S, Yeung M-W, Bas A et al. Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis. Clin Exp Immunol 2003 134 : 127 37.
22. Niessner M, Volk BA. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol 1995 101 : 428 35.
23. Mullin GE, Lazenby AJ, Harris ML, Bayless TM, James SP. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis. Gastroenterology 1992 102 : 1620 7.
24. Kusugami K, Matsuura T, West GA, Youngman KR, Rachmilewitz D, Fiocchi C. Loss of interleukin-2-producing intestinal CD4+ T cells in inflammatory bowel disease. Gastroenterology 1991 101 : 1594 605.
25. Autschbach F, Braunstein J, Helmke B et al. In situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease. Am J Pathol 1998 153 : 121 30.